Navigation Links
PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
Date:8/29/2013

SCHOFIELD, Wis., Aug. 29, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that it will discuss LipiGesic M on Armed Forces Network.

Studies show that thirty-seven percent of military veterans who are returning from combat zones suffer with migraine; this ratio is three to four times greater than that of the general population. These veterans with migraine are twice as likely to suffer Post-Traumatic Stress Disorder (PTSD). This creates a hardship for these veterans since the medications that are commonly used to treat PTSD are incompatible with the prescription medications currently used to treat migraine.

"The drug interactions between the PTSD medications and current prescription migraine treatments can be deadly," said Russ Mitchell, CEO of PuraMed BioScience. "We offer these veterans a highly effective alternative to treat their migraines since LipiGesic M has an excellent safety profile and has no reported drug interactions. It is important for veterans suffering both conditions to find treatment, since the symptoms of one will increase the symptoms of the other causing a vicious cycle. With LipiGesic M, veterans are now safe to treat migraine without having to sacrifice their treatment for PTSD."

LipiGesic M is an over-the-counter formulation of feverfew and ginger that has been clinically tested and found to provide rapid-relief from migraine headache and associated symptoms. When clinical trial results of LipiGesic M are compared to those of prescription medications, LipiGesic M is found to be as effective as the top-selling prescription migraine medication, but without the severe effects.

"We are honored that Armed Forces Network requested two interviews with us after they heard our broadcasts on the Big Biz Show," said Mitchell. "We know that LipiGesic M has been well received by the troops and has been battle tested on the frontlines in Afghanistan. It quickly became one of the most requested items in the care packages that were sent to the front. Since it does not cause severe or debilitating side effects, military personnel can take LipiGesic M and get back to the important work of defending our country."

About PuraMed BioScience, Inc.

PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches and LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com

Forward-Looking Statements

This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
Patricia McMurtrie
PuraMed BioScience
1326 Schofield Avenue
Schofield, WI 54476
715-571-4910
patricia@puramedbioscience.com


'/>"/>
SOURCE PuraMed BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
2. PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition
3. Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013
4. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
5. Sangamo BioSciences to Acquire Ceregene
6. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
7. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
8. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
9. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
10. Novel Use of Pressure BioSciences Patented PCT Platform Offers New Insights into Protein Structure and Function, New Tool for Biomarker Discovery and Rational Drug Design
11. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, ... 8th Day Software and Consulting, LLC , and named ... 8th Day Software, based in Tennessee , ... 8th Day expands EnvoyHealth,s service offerings for health care ... "In an interoperable ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud ... and unique items from across the nation, this holiday-themed event will raise funds and ... the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
Breaking Medicine News(10 mins):